NBO Pharma raised $7.64 million to advance its intranasal formulation of octreotide, a repurposed orphan drug in clinical trials for the treatment of idiopathic intracranial hypertension, a rare neurological condition with no currently approved therapies.
All entries for: Investment: Seed Run
December 5, 2025
Medicovestor
Investment: Seed Run
Medicovestor raised $3.16 million to advance ADoBind MC001, an FDA-designated orphan drug antibody-drug conjugate for the treatment of pancreatic cancer, a rare and highly aggressive malignancy with a five-year survival rate under 10%.
Disease Area: Rare Diseases
November 25, 2025
Repair Biotechnologies
Investment: Seed Run
Repair Biotechnologies raised $11.42 million to advance REP-0003, an FDA-designated orphan drug mRNA therapy for the treatment of homozygous familial hypercholesterolemia, an ultra-rare genetic disorder causing severely elevated cholesterol and accelerated atherosclerosis.
Disease Area: Rare Diseases
November 5, 2025
LambdaVision
Investment: Seed Run
LambdaVision raised $7 million to advance its protein-based artificial retina, a space-manufactured investigational device for the treatment of retinitis pigmentosa, a rare retinal degenerative disease.
Disease Area: Rare Diseases